Nonconvulsive status epilepticus featuring ictal paresis mimicking a stroke.

SeizureSep 11, 2026 (epub)
Case ReportNeurology

Philippe Gélisse, Pierre Henri Lefevre, Rosalie Boitet et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Wilson (1928) and Lennox (1960) described ictal paresis (IP) occurring during prolonged seizures that correspond to the modern definition of nonconvulsive status epilepticus (NCSE). This study aims to characterize this NCSE variant and clearly distinguish it from an acute stroke.

Reported results

Among the six patients, four had hemicorporeal deficits and two had isolated arm deficits. Other manifestations included sensory disturbances in three cases, mutism in five cases, and hemianopia in four cases. Two patients displayed perioral paresthesia. EEG showed ictal-interictal continuum patterns in three cases and focal/regional slowing in the other three.

Authors' conclusions

IP represents an under-recognized manifestation of NCSE. This study shows that perfusion-based neuroimaging is more sensitive than EEG for detecting ictal activity in this setting. We advocate for the routine inclusion of ASL sequences in the neuroimaging evaluation of patients with a suspected stroke and negative DWI findings.

Source

PubMed · PMID 42772079

Published in Seizure. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.